Other publications

Liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic cancer

Madappa N. Kundranda Genomic change index (GCI) and liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 33, 2015 (suppl 3; abstr 309).

Advanced PDAC is a lethal disease with dismal 5 year survival. The current modalities for monitoring therapy response using serum (CA) 19-9 levels have poor specificity and radiological responses have long lag times. Tests for rapid and accurate clinical assessment are needed for early decision making.

Prognostic value of cell-free DNA in patients with oropharyngeal cancers

Julia Beck, Margret Rave-Fraenk, et al. Prognostic value of cell-free DNA in patients with oropharyngeal cancers.J Clin Oncol 34, 2016 (suppl; abstr e17511).

Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.

Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.

Ekkehard Schütz, Julia Beck, Donald Peter Braun, Howard B. Urnovitz , et al. Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.J Clin Oncol 33, 2015 (suppl; abstr e22020) .

Genomic instability of tumor cells has been associated with a poor prognosis. However, impaired DNA repair pathways leading to genomic instability are also described to increase tumor sensitivity to DNA damaging agents. A comprehensive Genomic Change Index (GCI) as an indicator of defective DNA repair is proposed as a potential predictor of cytotoxic chemotherapy (chemo) response.

Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort.

Ekkehard Schütz, Howard B. Urnovitz, et al. Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort J Clin Oncol 31, 2013 (suppl; abstr 5072).

Prostate cancer (PrCa) is the most frequent non-dermatological malignancy in the male population. Genomic instability resulting in copy number variation (CNV) is a hallmark of malignant transformation.

Cell Free DNA accurately correlates with breast cancer DNA

Howard B. Urnovitz, Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 31, 2013 (suppl; abstr 11060)

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center announced results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients at the American Society of Clinical Oncology Annual Meeting (ASCO 2013).

Detection of novel HPV mutations and chromosomal number imbalance

Newswise

Newswise — CHICAGO (May 30, 2014) – Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral...